Promising Advancements in 4D Molecular Therapeutics’ Gene Therapy Programs Drive Buy Rating

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $36.00.

Matthew Caufield has given his Buy rating due to a combination of factors including the promising advancements in 4D Molecular Therapeutics’ pivotal gene therapy program for wet age-related macular degeneration (AMD). The initiation of Phase 3 trials, 4FRONT-1 and the anticipated 4FRONT-2, signifies a strategic move towards potentially transforming the treatment landscape for wet AMD. The company’s financial position is robust, with approximately $458 million in cash expected to support operations through the anticipated topline data release in the second half of 2027.
The Phase 1/2 PRISM trial results are particularly compelling, showing a significant reduction in injection burden for patients, which aligns with the priorities of retina specialists. Furthermore, the potential for maintaining anti-VEGF injection freedom for a majority of patients over 52 weeks highlights the clinical benefits of their approach. Additional catalysts include promising biomarker data and upcoming trial results for their other programs, such as 4D-150 in diabetic macular edema (DME) and 4D-710 in cystic fibrosis, which could further bolster the company’s position in the gene therapy space.

In another report released on May 9, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target.